CD172a antibody | 15-414
Mouse anti Human CD172 antibody, clone 15-414 (MCA2518) used for the demonstration of SIRPα expression on human thymus cells by immunofluorescence and flow cytometry.
Image caption:
Thymic Sirpα+DC-SIGN+ cDCs can uptake antigens, which leak inside the IVRs.
(A) Triple-color fluorescent image with the combination of Col IV (green), Ly-51 (blue), and Sirpα (red) in mouse thymic tissue. Dashed lines indicate the boundary between cortex (C) and medulla (M). Scale bar, 100 μm. (B) A double-color fluorescent immunostaining for DC-SIGN (green) and Sirpα (red) in human thymic tissue. Dashed lines indicate the outer margin of thymic lobule. Scale bar, 100 μm. (C) Thymic B220−CD11chighSirpα− (Sirpα−) and B220−CD11chighSirpα+ (Sirpα+) cDCs were sorted (Sirpα− purity, 97.8%; Sirpα+ purity, 97.1%) by using FACSAria (BD Biosciences), from thymic low-density cells isolated from 10 mice. Expression of DC-SIGN, SIGNR1, SIGNR2, SIGNR3, and SIGNR4 was determined by RT-PCR. GAPDH served as an internal positive control. RT-PCR analysis was repeated three times. (D) DC-SIGN expression on CD11chighSirpα− and CD11chighSirpα+ cDCs. Gray-filled and red-open histograms indicate the results obtained using isotype control and specific mAbs for DC-SIGN, respectively. (E) Thymi were collected at the indicated time points after FITC-conjugated dextran was intravenously injected into WT mice. Triple-color fluorescent images with the combination of dextran (green), DAPI (blue), and Col IV (red) are shown here. Scale bar, 200 μm. (F) Triple-color fluorescent images with the combination of dextran (green), Col IV (blue), and Sirpα (red) at 6 hrs after dextran injection are shown here. The confocal images in the parenchyma nearby small vessel and inside the IVRs, and superposed 3-D image inside the IVRs are shown in the upper and lower left, and lower right panels, respectively. Scale bars, 50 μm. (G) Uptake of OVA647 in low density cells at 4 hrs after injection. Percentage of CD11c (+) OVA647 (+) and CD11c (−) OVA647 (+) region are shown. Expression of Sirp&apha; molecule in region 1 (R1) and R2 are represented by unfilled and gray-filled histogram, respectively. (H) Uptake of OVA647 at 4 hrs after intravenous, subcutaneous, or intraperitoneal injection. Percentage of Sirp&apha; (+) OVA647 (+) region in thymic CD11chigh DCs is shown in each panel. PBS was injected as a control. Representative results from three independent experiments are shown here.
From: Baba T, Badr MES, Tomaru U, Ishizu A, Mukaida N (2012)
Novel Process of Intrathymic Tumor-Immune Tolerance through CCR2-Mediated Recruitment of Sirpα+ Dendritic Cells: A Murine Model.
PLoS ONE 7(7): e41154.
This image is from an open access article distributed under the terms of the Creative Commons Attribution License.
Mouse anti Human CD172 antibody, clone 15-414 (MCA2518) used for the demonstration of SIRPα expression on human thymus cells by flow cytometry.
Image caption:
Mice deficient in CCR2 gene exhibited reduced Treg differentiation and negative selection in the thymus.(A) Schematic representation of localization and function of thymic Sirpα+ cDCs. OVA protein uptake by CD11chighSirpα+ cDCs in WT and CCR2−/− thymus at 4 hrs after injection are shown. Percentage of Sirpα (+) OVA647 (−) and Sirpα (+) OVA647 (+) region are shown in each panel. (B) The uptake of OVA647 by CD11c+Sirpα+ cDCs derived from C57BL/6 thymi at 4 hrs after injection is shown in left panel. Sirp&apha;+ cDCs capturing OVA647 were separated into two groups according to the efficiency of OVA647 uptake; low and high. Percentages of cells in low and high regions in WT and CCR2−/− mice in BALB/c and C57BL/6 strain are shown in the right panel. Data represent mean ± SD from five and three independent experiments in BALB/c and C57BL/6 mice, respectively. (C) Expression of CD25 and Foxp3 on DO11.10high (R1) thymocytes at 2 days after OVA protein injection. Percentage of Foxp3 (+) region is shown in each panel. Representative results from three independent experiments are shown. (D) The numbers of Foxp3+ mature thymocytes were determined on DO11.10 and DO11.10/CCR2−/− mice at 2 days after OVA injection. Each symbol represents an individual mouse. Small horizontal lines indicate the mean. (E) Clonal deletion of thymocytes after OVA injection. Two mg OVA protein or heat-aggregated OVA protein were intravenously injected into DO11.10 mice. At 2 days after injection, the numbers of total thymocytes (left graph) and DP thymocytes (right graph) were determined on DO11.10 and DO11.10/CCR2−/− mice. Each symbol represents an individual mouse. **, p<0.01. *, p<0.05. N.S., no significant difference.
From: Baba T, Badr MES, Tomaru U, Ishizu A, Mukaida N (2012)
Novel Process of Intrathymic Tumor-Immune Tolerance through CCR2-Mediated Recruitment of Sirpα+ Dendritic Cells: A Murine Model.
PLoS ONE 7(7): e41154.
This image is from an open access article distributed under the terms of the Creative Commons Attribution License.
Filter by Application:
F IF ResetMouse anti Human CD172a
- Product Type
- Monoclonal Antibody
- Clone
- 15-414
- Isotype
- IgG2a
- Specificity
- CD172a
Antibody Quality and Performance Guarantee
| Mouse anti Human CD172a antibody, clone 15-414 recognizes human CD172a, also known as signal-regulatory protein alpha, a receptor-type transmembrane glycoprotein expressed on cells of myeloid origin, including granulocytes, dendritic cells (DCs), macrophages, mast cells and haematopoietic stem cells. CD172a acts as a substrate for several activated tyrosine kinases, including EGFR, PDGFR, src and insulin receptor and is involved in the negative regulation of receptor tyrosine kinase-coupled signaling pathways. Ligand binding of CD172a to integrin-associated protein CD47, results in tyrosine kinase phosphorylation of immunoreceptor tyrosine-based inhibitory motifs (ITIMs) within the cytoplasmic region of CD172a, mediating the recruitment and activation of the tyrosine phosphatases SHP-1 and SHP-2. These then act as regulators of cellular function, through dephosphorylation of specific substrates. Ligation of CD172a with CD47 has been demonstrated in several regulatory processes, including the inhibition of host cell phagocytosis by macrophages and the bi-directional activation of T cells and DCs. |
- Target Species
- Human
- Product Form
- Purified IgG - liquid
- Preparation
- Purified IgG prepared by affinity chromatography on Protein G from tissue culture supernatant
- Buffer Solution
- Phosphate buffered saline
- Preservative Stabilisers
- Pack Size: 0.1 mg
0.09% Sodium Azide (NaN3) Pack Size: 0.2 mg0.09% Sodium Azide (NaN3) - Carrier Free
- Yes
- Immunogen
- Monocyte-derived dendritic cells.
- Approx. Protein Concentrations
- IgG concentration 1.0mg/ml
- Fusion Partners
- Spleen cells from immunised Balb/c mice were fused with cells of the X63-Ag8.653 myeloma cell line.
- Regulatory
- For research purposes only
- Guarantee
- 12 months from date of despatch
This product is shipped at ambient temperature. It is recommended to aliquot and store at -20°C on receipt. When thawed, aliquot the sample as needed. Keep aliquots at 2-8°C for short term use (up to 4 weeks) and store the remaining aliquots at -20°C.
Avoid repeated freezing and thawing as this may denature the antibody. Storage in frost-free freezers is not recommended.
Avoid repeated freezing and thawing as this may denature the antibody. Storage in frost-free freezers is not recommended.
This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit the antibody protocols page.
| Application Name | Verified | Min Dilution | Max Dilution |
|---|---|---|---|
| Flow Cytometry |  |
1/100 Pack Size: 0.1 mg 1/25 Pack Size: 0.2 mg |
1/200 Pack Size: 0.1 mg 1/100 Pack Size: 0.2 mg |
| Immunofluorescence | |
||
| Immunohistology - Frozen | |
1/100 |
Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.
- Flow Cytometry
- Use 10ul of the suggested working dilution to label 1x106 cells in 100ul.
- Histology Positive Control Tissue
- Human tonsil.
| Description | Product Code | Applications | Pack Size | List Price | Your Price | Quantity | |
|---|---|---|---|---|---|---|---|
| Mouse IgG2a Negative Control | MCA929 | F | 100 Tests |
|
Log in | ||
| List Price | Your Price | ||||||
|
|
Log in | ||||||
| Description | Mouse IgG2a Negative Control | ||||||
References for CD172a antibody
-
Fujioka, Y. et al. (1996) A novel membrane glycoprotein, SHPS-1, that binds the SH2-domain-containing protein tyrosine phosphatase SHP-2 in response to mitogens and cell adhesion.
Mol Cell Biol. 16 (12): 6887-99. -
Baba, T. et al. (2012) Novel Process of Intrathymic Tumor-Immune Tolerance through CCR2-Mediated Recruitment of Sirpα(+) Dendritic Cells: A Murine Model.
PLoS One. 7: e41154. -
Szaraz, P.et al. (2016) In Vitro Differentiation of First Trimester Human Umbilical Cord Perivascular Cells into Contracting Cardiomyocyte-Like Cells
Stem Cells International. 2016: 1-13. -
Hussen, J. et al. (2014) The chemokine CCL5 induces selective migration of bovine classical monocytes and drives their differentiation into LPS-hyporesponsive macrophages in vitro.
Dev Comp Immunol. 47 (2): 169-77.
Further Reading
-
van Beek, E.M. et al. (2005) Signal regulatory proteins in the immune system.
J Immunol. 175 (12): 7781-7.
- Synonyms
- SIRP ALPHA
- RRID
- AB_1055630
- UniProt
- P78324
- Entrez Gene
- SIRPA
MCA2518GA
151904
MCA2518
151903
If you cannot find the batch/lot you are looking for please contact our technical support team for assistance.
View more products with CD172 specificity
Please Note: All Products are "FOR RESEARCH PURPOSES ONLY"
View all Anti-Human ProductsAlways be the first to know.
When we launch new products and resources to help you achieve more in the lab.
Yes, sign me up